Metformin glycinate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 577236

CAS#: 121369-64-0 (glycinate)

Description: Metformin glycinate is an AMP-activated protein kinase (AMPK) activator that improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose.

Chemical Structure

img
Metformin glycinate
CAS# 121369-64-0 (glycinate)
Instruction

Theoretical Analysis

MedKoo Cat#: 577236
Name: Metformin glycinate
CAS#: 121369-64-0 (glycinate)
Chemical Formula: C6H16N6O2
Exact Mass: 204.13
Molecular Weight: 204.230
Elemental Analysis: C, 35.29; H, 7.90; N, 41.15; O, 15.67

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1115-70-4 (HCl)   657-24-9 (free base)   121369-64-0 (glycinate)   34461-22-8 ( embonate)   58840-24-7 (orotate)   1384526-74-2 (icosapent)  

Synonym: Metformin glycinate

IUPAC/Chemical Name: N,N-Dimethyl-1,2,3-triimidodicarbonic diamide glycinate (1:1)

InChi Key: KOFRCHIVYXPUNL-UHFFFAOYSA-N

InChi Code: InChI=1S/C4H11N5.C2H5NO2/c1-9(2)4(7)8-3(5)6;3-1-2(4)5/h1-2H3,(H5,5,6,7,8);1,3H2,(H,4,5)

SMILES Code: CN(C)C(=N)NC(=N)N.NCC(=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 204.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sutter A, Landis D, Nugent K. Metformin has immunomodulatory effects which support its potential use as adjunctive therapy in tuberculosis. Indian J Tuberc. 2024 Jan;71(1):89-95. doi: 10.1016/j.ijtb.2023.05.011. Epub 2023 May 16. PMID: 38296396.


2: Kelleni MT. Repurposing metformin to manage idiopathic or long COVID Tinnitus: self-report adopting a pathophysiological and pharmacological approach. Inflammopharmacology. 2024 Jan 31. doi: 10.1007/s10787-023-01421-8. Epub ahead of print. PMID: 38294616.


3: Wang Q, Wei X. Research Progress on the Use of Metformin in Leukemia Treatment. Curr Treat Options Oncol. 2024 Jan 30. doi: 10.1007/s11864-024-01179-3. Epub ahead of print. PMID: 38286894.


4: Pedreañez A, Carrero Y, Vargas R, Hernandez-Fonseca JP, Mosquera-Sulbaran J. Paolo Brambilla, PhD, MD Possible role of metformin as an antidepressant in diabetes. Review. J Affect Disord. 2024 Jan 27:S0165-0327(24)00247-7. doi: 10.1016/j.jad.2024.01.228. Epub ahead of print. PMID: 38286229.


5: Xie H, Li M, Zheng Y. Associations of metformin therapy treatment with endometrial cancer risk and prognosis: A systematic review and meta-analysis. Gynecol Oncol. 2024 Jan 20;182:15-23. doi: 10.1016/j.ygyno.2024.01.007. Epub ahead of print. PMID: 38246042.


6: Dewangga R, Winston K, Ilhami LG, Indriani S, Siddiq T, Adiarto S. Association of metformin use with abdominal aortic aneurysm: A systematic review and meta-analysis. Asian Cardiovasc Thorac Ann. 2024 Jan 18:2184923231225794. doi: 10.1177/02184923231225794. Epub ahead of print. PMID: 38239055.


7: Pujalte-Martin M, Belaïd A, Bost S, Kahi M, Peraldi P, Rouleau M, Mazure NM, Bost F. Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759. Mol Oncol. 2024 Jan 12. doi: 10.1002/1878-0261.13583. Epub ahead of print. PMID: 38214418.


8: Almeida-Nunes DL, Silvestre R, Dinis-Oliveira RJ, Ricardo S. Enhancing Immunotherapy in Ovarian Cancer: The Emerging Role of Metformin and Statins. Int J Mol Sci. 2023 Dec 25;25(1):323. doi: 10.3390/ijms25010323. PMID: 38203494; PMCID: PMC10779012.


9: Alatawi AM. Metformin versus sodium glucose co-transporters inhibitors as first-line for atherosclerotic cardiovascular disease: A meta-analysis. Pak J Med Sci. 2024 Jan-Feb;40(1Part-I):209-213. doi: 10.12669/pjms.40.1.6982. PMID: 38196460; PMCID: PMC10772430.


10: Ruan G, Wu F, Shi D, Sun H, Wang F, Xu C. Metformin: update on mechanisms of action on liver diseases. Front Nutr. 2023 Dec 14;10:1327814. doi: 10.3389/fnut.2023.1327814. PMID: 38192642; PMCID: PMC10773879.


11: Zhao D, Sohouli MH, Rohani P, Fotros D, Velu P, Ziamanesh F, Fatahi S, Shojaie S, Li Y. The effect of metformin on adipokines levels: A systematic review and meta-analysis of randomized-controlled trials. Diabetes Res Clin Pract. 2023 Dec 26;207:111076. doi: 10.1016/j.diabres.2023.111076. Epub ahead of print. PMID: 38154535.


12: Sacco M, Ribaldone DG, Saracco GM. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction? Viruses. 2023 Dec 17;15(12):2451. doi: 10.3390/v15122451. PMID: 38140692; PMCID: PMC10748230.


13: Isop LM, Neculau AE, Necula RD, Kakucs C, Moga MA, Dima L. Metformin: The Winding Path from Understanding Its Molecular Mechanisms to Proving Therapeutic Benefits in Neurodegenerative Disorders. Pharmaceuticals (Basel). 2023 Dec 11;16(12):1714. doi: 10.3390/ph16121714. PMID: 38139841; PMCID: PMC10748332.


14: Rittenhouse BE, Alolayan S, Eguale T, Segal AR, Doucette J. The cost- effectiveness of metformin in the US diabetes prevention program trial: Simple interpretations need not apply. Prev Med. 2024 Jan;178:107819. doi: 10.1016/j.ypmed.2023.107819. Epub 2023 Dec 11. PMID: 38092328.


15: Cho M, Woo YR, Cho SH, Lee JD, Kim HS. Metformin: A Potential Treatment for Acne, Hidradenitis Suppurativa and Rosacea. Acta Derm Venereol. 2023 Dec 11;103:adv18392. doi: 10.2340/actadv.v103.18392. PMID: 38078688; PMCID: PMC10726377.


16: Chang W, Li W, Li P. The anti-diabetic effects of metformin are mediated by regulating long non-coding RNA. Front Pharmacol. 2023 Nov 20;14:1256705. doi: 10.3389/fphar.2023.1256705. PMID: 38053839; PMCID: PMC10694297.


17: Li R, Li H, Yang Z, Zhang X. Combination of metformin with liraglutide in treating HAIR-AN syndrome in children: A case report and literature review. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Sept 28;48(9):1425-1431. English, Chinese. doi: 10.11817/j.issn.1672-7347.2023.230100. PMID: 38044655.


18: Tiwari A, Kumar Singh R, Satone PD, Meshram RJ. Metformin-Induced Vitamin B12 Deficiency in Patients With Type-2 Diabetes Mellitus. Cureus. 2023 Oct 26;15(10):e47771. doi: 10.7759/cureus.47771. PMID: 38034222; PMCID: PMC10688235.


19: Huang Z, Li J, Chen H, Yu D, Sun S. The efficacy of metformin for the treatment of psoriasis: a meta-analysis study. Postepy Dermatol Alergol. 2023 Oct;40(5):606-610. doi: 10.5114/ada.2023.130524. Epub 2023 Aug 22. PMID: 38028405; PMCID: PMC10646712.


20: Lin H, Ao H, Guo G, Liu M. The Role and Mechanism of Metformin in Inflammatory Diseases. J Inflamm Res. 2023 Nov 23;16:5545-5564. doi: 10.2147/JIR.S436147. PMID: 38026260; PMCID: PMC10680465.